HOME >> MEDICINE >> NEWS
JCI table of contents, 1 August 2003

https://www.the-jci.org/press/17864.pdf


Increasing tolerance to contact allergens

Common contact allergies are triggered by allergens that affect the skin such as poison oak, poisin ivy, latex, dyes, fragrances, and metals. Researchers at the University of Mainz, Germany, have now shown that IL-10, a critical mediator of the immune response, is required in order to build-up tolerance to such allergens. The authors achieve what is known as low zone tolerance (LZT), in which repeated applications of low doses of contact allergens hinders the development of the allergic reaction. They demonstrate that mice lacking IL-10 cannot achieve LZT to allergens, suggesting that this IL-10driven response may be utilized in allergic therapies.

TITLE: Critical role of IL-10 in the induction of low zone tolerance to contact allergens

AUTHOR CONTACT:
Kerstin Steinbrink
University of Mainz, Mainz, Germany.
Phone: 49-6131-17-2297
Fax: 49-6131-17-6614
E-mail: steinbrink@hautklinik.klinik.uni-mainz.de

View the PDF of this article at: https://www.the-jci.org/press/18106.pdf


OutFoxing obesity

Obesity results from a massive expansion of fat cells. This expansion involves the differentiation of early precursor fat cells, known as preadipocytes, into mature fat cells. Researchers at Rockefeller University in New York have revealed that preadipocytes stably expressing the Foxa-2 protein do not differentiate into mature fat cells. Furthermore, in multiple rodent models of obesity they observed that Foxa-2 production is increased, in what may be an important counterregulatory mechanism to prevent the expansion of fat cell numbers. While the stimuli that induce Foxa-2 expression in mature fat cells is unknown, the authors propose that the pathways inv
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Aug-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Portable system offers dialysis patients liberating changes
2. Milk, fruits and vegetables may help reduce disability risk
3. Parents comfortable with vaccination for sexually transmitted infections for adolescent children
4. JCI table of contents, January 20 2005
5. Most adverse events in hospitalized children are preventable
6. Study finds no reduction in breast cancer risk with consumption of vegetables and fruits
7. Requip tablets treat symptoms of primary RLS
8. Medical negligence system is secretive, unaccountable and unregulated
9. Spina bifida: 70% of cases preventable by folic-acid supplementation
10. Determining which pancreatic cancers are treatable
11. Vegetable lovers should be viewed as different from fruit aficionados

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
Cached News: